MOSES 2.0 upgrade for HoLEP demonstrates cost savings in BPH

The guideline includes 38 recommendations on managing incontinence following treatment for localized prostate cancer or benign prostatic hyperplasia.

The data were presented at the recent American Urological Association Annual Meeting.

"From a learning curve standpoint, there's not much to learn. It tends to be fairly quick in terms of your ability to do the procedure," says Matthew E. Sterling, MD.

“Even though there [are] many therapies that one can do, it's not a sign of anything ominous for most men,” says Kevin T. McVary, MD, FACS.

"The results showed the contemporary Aquablation procedural safety in Japanese men is exceptional in a broad range of prostate sizes along with significant symptom reduction," says Nobuyuki Hinata, MD.

iTind is a temporary nitinol device used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia.